Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-03
2009-12-08
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S379100, C548S379400, C548S379700
Reexamination Certificate
active
07629373
ABSTRACT:
The present invention relates to fluorinated dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
REFERENCES:
patent: 6774127 (2004-08-01), Adams et al.
patent: WO 03/079973 (2003-10-01), None
patent: WO 2006/007496 (2006-01-01), None
patent: WO 2006/101761 (2006-09-01), None
Patani, George A. Bioisosterism: A rational approach in drug design. Chem. Rev. 96 (1996) 3147-3176.
Coleman Paul J.
Cox Christopher D.
Beeler Nicole M.
Merck & Co. , Inc.
Muthard David A.
Saeed Kamal A
Shterengarts Samantha L
LandOfFree
Mitotic kinesin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mitotic kinesin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mitotic kinesin inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4116463